# US 11,078,201 B2 · Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,078,201 B2
- Document ID: US11078201B2
- Status: Granted
- Kind: B2
- Application number: 17/020,013
- Filed: 2020-09-14
- Published: 2021-03-18
- Granted: 2021-08-03
- Earliest claimed: 2019-09-13
- Assignees: Nimbus Saturn, Inc.
- Applicants: Nimbus Saturn, Inc.
- Inventors: Neelu Kaila; Ian Linney; Stuart Ward; Grant Wishart; Ben Whittaker; Alexandre Cote; Jeremy Robert Greenwood; Abba Leffler; Steven K. Albanese; Daniel L. Severance
- Web page: https://patentgrep.com/patent/US11078201B2

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07B 2200/07: Optical isomers
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.

## Claims

### Claim 1

A compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein said compound is
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein said compound is
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein said compound is
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein said compound is
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound of claim 1, wherein said compound is
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The compound of claim 1, wherein said compound is
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The compound of claim 1, wherein said compound is
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

The compound of claim 1, wherein said compound is
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

The compound of claim 1, wherein said compound is
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

The compound of claim 1, wherein said compound is
or a pharmaceutically acceptable salt thereof.

### Claim 12

A pharmaceutical composition comprising a compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 14 (depends on 12)

The pharmaceutical composition of claim 12, wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 15 (depends on 12)

The pharmaceutical composition of claim 12, wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 16 (depends on 12)

The pharmaceutical composition of claim 12, wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 17 (depends on 12)

The pharmaceutical composition of claim 12, wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 18 (depends on 12)

The pharmaceutical composition of claim 12, wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 19 (depends on 12)

The pharmaceutical composition of claim 12, wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 20 (depends on 12)

The pharmaceutical composition of claim 12, wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 21 (depends on 12)

The pharmaceutical composition of claim 12, wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

### Claim 22 (depends on 12)

The pharmaceutical composition of claim 12, wherein said compound is
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.